Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.67 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.67 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.67 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.67 |
| ▸ | SRC | P12931 | 3/20 | 0.67 |
| ▸ | EGFR | P00533 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | WEE1 | P30291 | 8/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.48 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423133 | 0.88 | SRC (0.66) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL5762370 | 0.84 | FGFR1 (0.64) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL5764510 | 0.83 | FGFR1 (0.50) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL5763591 | 0.82 | SRC (0.77) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL21990257 | 0.81 | ABL1 (0.53) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL5065441 | 0.81 | FGFR1 (0.60) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL20563978 | 0.80 | ABL1 (0.52) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL4839269 | 0.80 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL30837130 | 0.80 | ABL1 (0.52) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL27218134 | 0.80 | FGFR4 (1.00) | FGFR1FGFR2FGFR4FGFR3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2005105097-A2 | PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES | GPC BIOTECH AG (DE) | 2005-11-10 | — | — | WO | claimed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | claimed |
| US-5620981-A | ANTICARCINOGENIC AGENTS, ATHEROSCLEROSIS, RESTENOSIS, PSORIASIS | WARNER-LAMBERT COMPANY (US) | 1997-04-15 | — | — | US | claimed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | claimed |
| US-20140163007-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163222-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163005-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163003-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2009130015-A1 | IMPROVED RAF INHIBITORS | GPC BIOTECH AG (DE) | 2009-10-29 | — | — | WO | disclosed |
| EP-2112150-A1 | Improved raf inhibitors | GPC Biotech AG (DE) | 2009-10-28 | — | — | EP | disclosed |
| EP-2084159-A1 | PYRIDO Ý2, 3-D¨PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | GPC Biotech Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008150260-A1 | 8-OXY-2-AMINOPYRIDO (2, 3-D) PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND ANTICANCER AGENTS | GPC BIOTECH, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008047307-A1 | PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | GPC BIOTECH INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-1914234-A1 | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors | GPC Biotech Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005105097-A2 | PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES | GPC BIOTECH AG (DE) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885FGFR2 919/4885FGFR4 719/4885 |
| US-20140163003-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885FGFR2 919/4885FGFR4 719/4885 |
| US-20140163007-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885FGFR2 919/4885FGFR4 719/4885 |
| US-20140163005-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885FGFR2 919/4885FGFR4 719/4885 |
| US-20140163222-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885FGFR2 919/4885FGFR4 719/4885 |
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885FGFR2 919/4885FGFR4 719/4885 |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885FGFR2 919/4885FGFR4 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.